Two companies, Concord Control Systems Ltd. and Welcure Drugs & Pharmaceuticals , have set October 16 as the record date for their respective bonus share distributions, subject to shareholder approval. Additionally, Welcure Drugs & Pharmaceuticals has announced a stock split.

Bonus Share Details

Stock Split Announcement

Welcure Drugs & Pharmaceuticals Ltd. has also proposed a stock split in a 1:10 ratio. This means:

• Current: 1 share with a face value of Rs 10.00
• After split: 10 shares with a face value of Rs 1.00 each

Important Note for Investors

Under India's T+1 settlement cycle, investors must purchase shares at least one trading day before the record date (October 16) to be eligible for the bonus allocation.

What This Means for Shareholders

Concord Control Systems Ltd.

Shareholders will receive a significant increase in their shareholding, with 5 new shares for every 3 they currently own.

Welcure Drugs & Pharmaceuticals Ltd.

• Bonus Issue: Shareholders will see a substantial multiplication of their shares, receiving 10 new shares for each existing share.
• Stock Split: The number of shares will increase tenfold, potentially improving liquidity and making the stock more accessible to smaller investors.

These corporate actions aim to reward existing shareholders and potentially increase market liquidity for both stocks. However, it's important to note that while the number of shares will increase, the overall value of a shareholder's stake in the company remains the same, as the stock price typically adjusts proportionately after such actions.

Investors interested in these corporate actions should ensure they complete their share purchases by the last trading day before the record date to be eligible for the bonus shares.

Welcure Drugs & Pharmaceuticals Ltd has announced a change in the date of its crucial board meeting, originally scheduled for September 25, 2025. The company has rescheduled the meeting to September 27, 2025, citing the unavailability of directors as the reason for the postponement.

Key Agenda Items

The upcoming board meeting is set to discuss several significant matters:

1. Potential Stake Acquisition: The board will deliberate on a Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore. The proposal outlines a potential acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals at ₹20.00 per share, representing a substantial premium over the current market price.

2. Due Diligence Process: Initiation of a comprehensive due diligence process for the proposed transaction, covering legal, financial, and regulatory aspects.

3. Negotiation Authorization: The board will consider authorizing company representatives to negotiate and finalize terms of definitive agreements, ensuring alignment with Welcure Drugs & Pharmaceuticals' long-term growth strategy and regulatory compliance.

4. Shareholder Approval Mechanisms: Exploration of mechanisms for obtaining shareholder approval, potentially through postal ballot or general meeting, in accordance with SEBI, RBI, FEMA, and stock exchange requirements.

5. Strategic Growth Opportunities: Discussions on future strategic growth prospects in global pharmaceutical and chemical exports, leveraging Telexcell's global trade network.

Regulatory Compliance

The company has duly informed the BSE Limited about the postponement, adhering to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Statement

Chintan Didawala Ganpat, Managing Director of Welcure Drugs & Pharmaceuticals Ltd, signed the official communication to the stock exchange, emphasizing the company's commitment to transparency and regulatory compliance.

The rescheduled board meeting on September 27, 2025, is expected to be a pivotal event for Welcure Drugs & Pharmaceuticals, potentially shaping its future strategic direction and ownership structure. Stakeholders will be keenly watching the outcomes of this meeting, particularly regarding the proposed stake acquisition by Telexcell Trade PTE LTD and its implications for the company's global expansion plans.